No Increase Seen in Neurodevelopmental Disorders With Prenatal Triptan Use
By Elana Gotkine HealthDay Reporter
WEDNESDAY, May 21, 2025 -- Children prenatally exposed to different triptan intensities and duration, alone or in combination with other preventive medications for migraine, do not have increased risk of neurodevelopmental outcomes, according to a study published online May 21 in Neurology.
Margherita Camanni, from the University of Milano-Bicocca in Italy, and colleagues examined the effect of different intensities and durations of prenatal exposure to triptans on neurodevelopmental disorders (NDDs) in children in a nationwide health registry study including pregnancies of women with migraine before pregnancy.
Data were included for 26,210 pregnancies of women with migraine: 4,929 were nonmedicated and 21,281 were medicated with triptans in the year of prepregnancy. The researchers identified four group-based trajectories of triptans alone and combined with preventive medications: discontinuers before (low use), early discontinuers (short-term low use), late discontinuers (moderate use), and late discontinuers (high use). During follow-up (mean, eight years), 4.3 percent of the children had a NDD. Compared with children of nonmedicated women, children born to women with any triptan trajectory had a slightly higher risk of NDD (magnitude range of the weighted hazard ratio, 1.05 to 1.16). When discontinuers before (low use) acted as a comparator or when analyzing speech/language disorders or attention-deficit/hyperactivity disorder, these risks decreased to null. The risk of autism disorders was slightly, but not significantly, elevated with both triptan late discontinuation trajectories.
"Our results contribute to the limited existing literature and aid pregnant women with migraine and their health care providers in making evidence-based decisions about pharmacologic treatment with triptans and other migraine medications during gestation," the authors write.
Abstract/Full Text (subscription or payment may be required
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Liraglutide May Reduce Migraine Burden in Adults With Obesity, Migraine
MONDAY, June 30, 2025 -- For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and Migraine Disability...
Arsenic Less Than EPA Maximum Contaminant Level Tied to Adverse Birth Outcomes
THURSDAY, June 26, 2025 -- Arsenic measured in public water systems at levels below the current U.S. Environmental Protection Agency's maximum contaminant level are associated...
Paternal Mental Distress Linked to Poorer Offspring Development
WEDNESDAY, June 25, 2025 -- Paternal mental distress is associated with poorer child development, according to a study published online June 16 in JAMA Pediatrics. Genevieve Le...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.